Background Oral corticosteroids (OCS) are commonly administered in patients with severe
persistent allergic asthma. Despite their efficacy, they are associated with a wide variety of …

BACKGROUND: Long-term oral corticosteroid (OCS) therapy is associated with significant
burden on patients and healthcare resources; treatments that may help reduce their use are …

BACKGROUND: Asthma guidelines advocate maintaining asthma control while minimizing
corticosteroid exposure. OBJECTIVE: To assess the reduction in corticosteroid burden …

Background: Long-term oral corticosteroid (OCS) therapy and related adverse events are
associated with a significant burden on patients and healthcare resources. Methods: This …

Background Omalizumab is a non-steroidal medication indicated for the treatment of poorly
controlled moderate-to-severe allergic asthmatics. This observational study examines the …

Background: Allergic asthma is an immunoglobulin E (IgE)-mediated disease characterized
by frequent exacerbations following exposure to relevant allergens that leads to the …

Abstract Background Omalizumab, an anti-IgE monoclonal antibody, is administered by
injection once or twice monthly in offices and clinics. It offers a potential alternative …

Aims There are no specific criteria for a step‐down or withdrawal dose of omalizumab
(OMA). Our purpose was to evaluate the viability of a protocol for OMAlizumab DOse …

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic
asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month …

Objective. Approved by the FDA in 2003, omalizumab is the first recombinant humanized
monoclonal anti-immunoglobulin E antibody developed for the treatment of allergic asthma …